The prognostic value of the tumor-stroma ratio compared to tumor-infiltrating lymphocytes in triple-negative breast cancer: a review
Authors:
Open Access
- 4 February 2025
- journal article
- review article
- Published by Springer Nature in Virchows Archiv
- Vol. 486 (3) , 427-444
Abstract
Previous literature extensively explored biomarkers to personalize treatment for breast cancer patients. The clinical need is especially high in patients with triple-negative breast cancer (TNBC) due to its aggressive nature and limited treatment modalities. This review aims to evaluate the value of tumor-infiltrating lymphocytes (TILs) and tumor-stroma ratio (TSR) as prognostic biomarkers in TNBC patients and assess their clinical potential. A literature search was conducted in PubMed, Embase, Emcare, Web of Science, and Cochrane Library. Papers comparing survival outcomes of TNBC patients with low/high or negative/positive TSR and immune cells were included. The most frequently mentioned subgroups of TILs were selected and reported in this review. Data from 43 articles on TILs and eight articles on TSR were included. Among TNBC patients, high CD8 expression was generally associated with better survival. Notable, the poor survival outcomes were related to high intra-tumoral PD-L1 expression, whereas high stromal PD-L1 expression more often was correlated with favorable outcomes. For the TSR, a high amount of stroma in the primary tumor of TNBC patients was consistently associated with worse survival. This review highlights that a high number of CD8-positive T-cells is a promising prognostic factor for TNBC patients. PD-L1 expression analyzed for intra-tumoral and stromal expression separately reports strong but contrasting information. Finally, the TSR shows potential to be an important prognostic marker, especially for TNBC patients. Utilizing both biomarkers, either on itself or combined, could enhance clinical decision-making and personalization of treatment.Keywords
Funding Information
- Bollenstreekfonds
This publication has 134 references indexed in Scilit:
- Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancerVirchows Archiv, 2023
- Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancerInternational Journal of Cancer, 2021
- Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?Cancer Immunology, Immunotherapy, 2020
- The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancerInternational Journal of Cancer, 2020
- Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancerJournal of Cancer Research and Clinical Oncology, 2019
- The prognostic value of tumor–stroma ratio in tumor‐positive axillary lymph nodes of breast cancer patientsInternational Journal of Cancer, 2018
- The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based studyInternational Journal of Colorectal Disease, 2018
- PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapyInternational Journal of Cancer, 2017
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursThe Journal of Pathology, 2013
- Smooth‐muscle differentiation in stromal cells of malignant and non‐malignant breast tissuesInternational Journal of Cancer, 1988